Last reviewed · How we verify
Spartalizumab in Pediatric cohort
Spartalizumab in Pediatric cohort is a Small molecule drug developed by University Hospital, Bordeaux. It is currently in Phase 1 development.
At a glance
| Generic name | Spartalizumab in Pediatric cohort |
|---|---|
| Sponsor | University Hospital, Bordeaux |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Spartalizumab and Low-dose PAzopanib in Refractory or Relapsed Solid TumOrs of Pediatric and Adults (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Spartalizumab in Pediatric cohort CI brief — competitive landscape report
- Spartalizumab in Pediatric cohort updates RSS · CI watch RSS
- University Hospital, Bordeaux portfolio CI
Frequently asked questions about Spartalizumab in Pediatric cohort
What is Spartalizumab in Pediatric cohort?
Spartalizumab in Pediatric cohort is a Small molecule drug developed by University Hospital, Bordeaux.
Who makes Spartalizumab in Pediatric cohort?
Spartalizumab in Pediatric cohort is developed by University Hospital, Bordeaux (see full University Hospital, Bordeaux pipeline at /company/university-hospital-bordeaux).
What development phase is Spartalizumab in Pediatric cohort in?
Spartalizumab in Pediatric cohort is in Phase 1.